Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth

KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important therapeutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence and makes a double-strand break, which enables editing of the releva...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Genome Res
Main Authors: Kim, Wonjoo, Lee, Sangeun, Kim, Han Sang, Song, Minjung, Cha, Yong Hoon, Kim, Young-Hoon, Shin, Jeonghong, Lee, Eun-Seo, Joo, Yeonsoo, Song, Jae J., Choi, Eun Ju, Choi, Jae W., Lee, Jinu, Kang, Moonkyung, Yook, Jong In, Lee, Min Goo, Kim, Yeon-Soo, Paik, Soonmyung, Kim, Hyongbum (Henry)
Formato: Artigo
Idioma:Inglês
Publicado: Cold Spring Harbor Laboratory Press 2018
Assuntos:
Method
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848616/
https://ncbi.nlm.nih.gov/pubmed/29326299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gr.223891.117
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares